Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

miRNA-21a inhibitor and application thereof in preparing medicine for delaying myocardial infarction

A technology of miRNA-21a and myocardial infarction, applied in the fields of biotechnology and medicine, can solve the problems of poor treatment and prevention of early inflammation after myocardial infarction

Inactive Publication Date: 2016-10-12
SHANGHAI EAST HOSPITAL
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Aiming at the above-mentioned technical problems in the prior art, the present invention provides a miRNA-21a inhibitor and its use in the preparation of a drug for delaying myocardial infarction, the miRNA-21a inhibitor and its use in the preparation of a drug for delaying myocardial infarction The use in the medicine should solve the technical problem that the medicine in the prior art is not effective in the treatment and prevention of early inflammation after myocardial infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • miRNA-21a inhibitor and application thereof in preparing medicine for delaying myocardial infarction
  • miRNA-21a inhibitor and application thereof in preparing medicine for delaying myocardial infarction
  • miRNA-21a inhibitor and application thereof in preparing medicine for delaying myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The sequence of miRNA-21a is 5'-UAGCUUAUCAGACUGAUGUUGA-3', and the miRNA-21a inhibitor is designed as a single-stranded RNA oligonucleotide, and its sequence design follows the principle of reverse complementarity with the sequence of miRNA-21a, that is, 5'- UCAACAUCAGUCUGAUAAGCUA-3'. The inhibitor control sequence was designed as 5'-UUGUACUACACAAAAGUACUG-3', which had no homology or complementarity with mouse and human sequences after Blast retrieval. The miRNA-21a inhibitor and control were chemically synthesized by Guangzhou Ruibo Biotechnology Co., Ltd., and the whole chain was modified with 2'-methoxy (2'-O-Me) to improve its stability.

Embodiment 2

[0021] Example 2: Up-regulation of miRNA-21a expression in the myocardial tissue of the myocardial infarction border zone after myocardial infarction in mice

[0022] Mice (C57 strain, male, 8-10 weeks old, purchased from Shanghai Xipuer-Bikay Experimental Animal Co., Ltd.), established a myocardial infarction model according to the method reported in the literature [Tarnavski, O. et al., Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics. 2004; 16; 349-360], the mice in the sham operation group were only threaded but not ligated the anterior descending branch when establishing the myocardial infarction model. Myocardial tissues in the border area of ​​myocardial infarction were collected from mice at 3 days, 5 days and 7 days after myocardial infarction.

[0023] The expression of miRNA-21a in myocardial tissue in the border zone of myocardial infarction was analyzed ...

Embodiment 3

[0031] Example 3: miRNA-21a inhibitor inhibits the production of inflammatory cytokines in the myocardial tissue of the border zone of myocardial infarction in mice

[0032] Mice (C57 strain, male, 8-10 weeks old, purchased from Shanghai Nanfang Model Organism Research Center), the mouse myocardial infarction model was prepared as described in Example 1, and the myocardial infarction tissue was locally injected with an adenovirus carrying a miRNA-21a inhibitor Adenoviral vector (synthesized by Shanghai Heyuan Biotechnology Co., Ltd.) was inhibited by vector and control. Myocardium tissue in the normal area of ​​myocardial infarction and myocardial tissue in the borderline area of ​​myocardial infarction were collected from mice 3 days, 5 days, and 7 days after myocardial infarction, respectively.

[0033] The expression of inflammatory cytokines in myocardial tissue of myocardial infarction was analyzed by real-time quantitative reverse transcription-PCR (qRT-PCR). Tissue tota...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine, and provides an miRNA-21a inhibitor. The nucleotide sequence of the miRNA-21a inhibitor is shown as SEQ ID NO:1. The invention further provides application of the miRNA-21a inhibitor in preparing medicine for inhibiting myocardial infarction early stage inflammation or delaying the development of myocardial infarction early stage inflammation. The expression of miRNA-21a in the early stage of myocardial infarction is significantly increased, and the miRNA-21a inhibitor can inhibit myocardial infarction and inflammation increase caused by related factors and perform the anti-inflammation function for myocardial infarction in the early stage when applied internally or externally. The miRNA-21a inhibitor can be applied to preparing medicine for inhibiting myocardial infarction early stage inflammation or delaying the development of myocardial infarction.

Description

technical field [0001] The invention belongs to the fields of biotechnology and medicine, and relates to an inhibitor of small RNA molecules, specifically an inhibitor of miRNA-21a and its application in the preparation of drugs for delaying myocardial infarction. Background technique [0002] Ischemic heart disease, such as myocardial infarction, has a high incidence rate, high morbidity and mortality, and is one of the main diseases that endanger human health. According to statistics, there are 500,000 new patients with myocardial infarction in my country every year, and the current number of patients is 2.5 million, of which 1 / 2 have lost their ability to work [Chinese Cardiovascular Disease Report, Chen Weiwei et al., Encyclopedia of China Publishing House, 2014] . The most effective treatment after myocardial ischemia is to restore the blood flow in the ischemic area as soon as possible. However, in fact, the injury of the ischemic myocardium after recovery and reperfus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K31/7105A61P9/10
CPCA61K31/7105
Inventor 占贞贞杨琳珊刘中民
Owner SHANGHAI EAST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com